Comparison of In vivo toxicity and anti-glatiramer acetate IgG antibody titers in rats Treated with glatiramer acetate (Copaxone) and follow-on glatiramer acetate (FOGA) products

被引：0
|
作者：
Konya, A. [1 ]
Timan, B. [2 ]
Ashkenazi, N. [2 ]
Bursztyn, D. [2 ]
Gyure, L. [1 ]
Vardi, M. [2 ]
Alexander, J. [3 ]
Loupe, P. [4 ]
Nock, S. [5 ]
机构：
[1] Teva Pharmaceut Ind Ltd, Debrecen, Hungary
[2] Teva Pharmaceut Ind Ltd, Netanya, Israel
[3] Teva Pharmaceut Ind Ltd, Denver, CO USA
[4] Teva Pharmaceut Ind Ltd, Overland Pk, KS USA
[5] Teva Pharmaceut Ind Ltd, Redwood City, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P678
引用
收藏
页码：337 / 337
页数：1
相关论文
共 43 条
  • [41] Efficacy and safety of generic glatiramer acetate Timexon® : results of the 12-month extension of BCD-063-1 international double-blind randomized placebo-controlled clinical study of efficacy and safety of Timexon® in comparison with Copaxone®
    Boyko, A.
    Zakharova, M.
    Kotov, S.
    Khabirov, F.
    Sazonov, D.
    Trinitatsky, Y.
    Zinkina-Orikhan, A.
    Tursunova, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 340 - 340
  • [42] Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multi-national extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
    Rovaris, M
    Comi, G
    Rocca, M
    Ladkani, D
    Valsasina, P
    Pieri, E
    Shifroni, G
    Wolinsky, JS
    Filippi, M
    JOURNAL OF NEUROLOGY, 2005, 252 : 41 - 41
  • [43] Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multi-national extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
    Rovaris, M
    Comi, G
    Rocca, MA
    Ladkani, D
    Valsasina, R
    Pieri, E
    Shifroni, G
    Wolinsky, JS
    Filippi, M
    MULTIPLE SCLEROSIS, 2005, 11 : S84 - S84
12345